An Alzheimer’s Drug Approved For The First Time In 18 Years

Serving the United States Department of Health FDA (Food and Drug Administration), nearly 20 years later, has signed a first. The institution, produced by the US-based biotechnology company Biogen,AduhelmHe approved the use of the Alzheimer’s drug ”. This historical approval given by the FDA has made a sound all over the world.

Shares of Biogen, manufacturer of the drug Aduhelm, with FDA approval Increases of up to 60% even saw it. Making a statement on the subject, President of the FDA Center for Drug Evaluation and Research, Dr. Patrizia Cavazzoni stated that they understand that Aduhelm has caught the attention of the press, the Alzheimer’s patient community, authorities and other relevant stakeholders.

A first since 2003:

The FDA has announced that it will continue to monitor the drug once it is released to the US market. If the institution is for the use of the drug an important condition he ran. Biogen with drug approval by conducting another clinical trial held liable. Messages showing joy were also given from Alzheimer’s communities regarding the approval of the drug.

Harry Jones, CEO of the American Alzheimer’s Association, said in a statement:This is a new day. This endorsement ensures that people living with Alzheimer’s have more time to live better. For families, it means being able to hold on to their loved ones longer. It’s about reinvigorating scientists and companies in the fight against a scourge of disease. It’s about hope.” he said.

Aduhelm, which is the first drug approved for Alzheimer’s since 2003, slows the progression of mild cognitive impairment. The drug focuses on slowing the progression of the disease rather than alleviating its symptoms. Biogen, the manufacturer of the drug, said in a statement that Aduhelm’s list price $56,000/year announced it would.